Why Ascelus ?

15M people in England and 133M people in the US are living with an LTC (including cancer).

Healthcare systems are under a huge capacity and financial strain because demand for LTC management continues to growand is outpacing supply. This results in longer waiting times, reduced quality of care and insufficient time for patients with more complex needs.

For Commissioners / payers, costs are rising faster than growth of budgets and an increasing proportion of budget is on LTCs.

Empowering Patients: The Ascelus Patient Mobile App

Patients take an active role in managing their health with the Ascelus mobile app, a personalised companion for managing their long-term condition. Designed with patients’ needs in mind, the app offers a suite of features to help them stay informed, engaged, and in control of their health journey.

Key Features:

Convenient a-synchronous virtual reviews: Patients can connect with their healthcare provider through secure, asynchronous virtual consultations. These quick and efficient check-ins replace the need for some traditional face-to-face appointments, freeing up patients’ time.

Self-Management Tools: The app empowers patients with tools and resources to manage their condition effectively. This may include medication reminders, symptom trackers and educational materials.

Real-Time Self-Monitoring: Patients can easily monitor their health status. The app allows them to submit data on key health indicators and track trends over time. This data is also accessible to their clinician, fostering a collaborative approach to care.

Secure Communication: Information patients enter into the Ascelus is securely shared with their healthcare provider through the app’s secure messaging system, allowing for safe, clear and timely communication.

Appointment Management: Patients can conveniently schedule and view upcoming appointments within the app. They can also access past appointment details and notes.

Available Anywhere, Anytime: Patients can access the Ascelus App on their smartphone (Android or iOS) or tablet for a convenient and mobile-friendly experience. Patients without a smart phone or tablet can still utilise the platform through a web browser on a computer, ensuring everyone can benefit from Ascelus, regardless of device preference.

Many long-term conditions present a complex puzzle for patients and healthcare professionals alike. While some patients experience stable conditions, others progress to more severe stages. Unfortunately, current methods to measure a patient’s risk of disease progression are imprecise and fail to capture the complexity and variability among patients.

Ascelus AI, a revolutionary AI-powered tool in development, can extract meaningful patterns from complex datasets, surpassing human capabilities in identifying subtle correlations. Ascelus-AI is poised to transform how we manage LTCs by offering:

Personalised Risk Assessments: Ascelus AI analyses a broader range of data, including dynamic trends in clinical data (such as biomarkers and haemoglobin trajectories), patient history and patient-reported symptoms. This allows for highly individualised risk assessments, empowering patients with knowledge about their specific condition and reducing anxiety associated with the unknown.

Earlier Intervention Potential: By identifying high-risk patients more accurately, clinicians can intervene earlier, potentially improving patient outcomes and preventing disease progression.

Targeted Monitoring: Ascelus AI optimises monitoring schedules based on individual risk. This reduces unnecessary procedures, improving patient comfort and streamlining healthcare delivery.

Efficient Resource Allocation: More accurate risk stratification allows healthcare systems to allocate resources more effectively, ensuring high-risk patients receive the care they need while minimising unnecessary interventions for low-risk patients.

Ascelus AI empowers patients with knowledge, optimises care delivery for clinicians, and ensures efficient resource allocation for healthcare systems.